The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.
about
Prostate cancer: ESMO Consensus Conference Guidelines 2012A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.Conversion to monotherapy with luteinizing-hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression-free survival in patients with metastatic prostate cancer: A propEfficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysisGrowth of LAPC4 prostate cancer xenograft tumor is insensitive to 5α-reductase inhibitor dutasteride.The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatmentAdoption of Intermittent Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study in American Urology Practice.Intermittent versus continuous androgen deprivation in prostate cancerIntermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.Intermittent androgen deprivation therapy in advanced prostate cancer.Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis.The role of intermittent androgen deprivation therapy in the management of biochemically recurrent or metastatic prostate cancer.Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy.The role of androgen deprivation therapy plus radiation therapy in patients with non-metastatic prostate cancer.Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial.Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII.International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries.Intermittent, low-dose, antiandrogen monotherapy as an alternative therapeutic option for patients with positive surgical margins after radical prostatectomy.
P2860
Q27022847-94A79BC9-C0E0-4E8D-B4DA-10603EB414BBQ30780322-9406E422-4C28-450F-AEDF-9DD7C585DB8DQ33750752-1CE89C2E-9989-4ABA-8989-F899C5494E4EQ34133868-36C960A2-7FA1-4F31-A77E-F5FB97E49690Q34448181-6C741BC1-0CA8-4591-80E8-2BD076454FADQ36177105-18B53D06-4F85-4B02-9354-10D5CCD82DAAQ36623249-55F22C14-8EE4-4AEE-9D75-97C7D3B9F649Q36929295-DED1D81C-5BCE-4DBB-B427-8A8BC0E74CC7Q37554029-646798CD-E4DE-4985-8A17-BB697861AC94Q37592301-FA65D4E7-CC62-438C-9F05-79E03BC5E141Q38176254-76B0F047-F4F9-4D76-AE60-6879F8C7B56CQ38179060-E3238739-AA04-4EA0-B145-AFC63DE77628Q38200898-FB9123E5-34EC-4800-BA45-E9F614D813C6Q38353806-89D7BF44-D9C5-4E97-9A47-1D678B8E8721Q38353828-CB8E6BDD-8E51-4937-ADB8-9A2359E55A72Q38910225-F969FE0E-D448-499C-AD19-10FE8F0EB6D5Q45795876-FEBAFF84-8A08-4824-BDD3-B6D5AF00C9B2Q48081685-4AABFE6D-C3A7-4975-BD2D-656FBE608DB4Q54917990-9C486602-56B6-45BB-BD8C-027CC9EED7B7Q55129526-406F85BD-2C22-405F-8E36-DB8FE222AF3E
P2860
The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The FinnProstate Study VII: in ...... with advanced prostate cancer.
@en
The FinnProstate Study VII: in ...... with advanced prostate cancer.
@nl
type
label
The FinnProstate Study VII: in ...... with advanced prostate cancer.
@en
The FinnProstate Study VII: in ...... with advanced prostate cancer.
@nl
prefLabel
The FinnProstate Study VII: in ...... with advanced prostate cancer.
@en
The FinnProstate Study VII: in ...... with advanced prostate cancer.
@nl
P2093
P1476
The FinnProstate Study VII: in ...... with advanced prostate cancer.
@en
P2093
Arto J Salonen
FinnProstate Group
Jouko Viitanen
Martti Ala-Opas
Seppo Lundstedt
Teuvo L J Tammela
P304
P356
10.1016/J.JURO.2012.01.122
P407
P50
P577
2012-04-11T00:00:00Z